News & Updates

Paediatric specialists now use low-dose EuroLupus cyclophosphamide (CYC) more than they did a decade ago in the treatment of childhood-onset systemic lupus erythematosus (cSLE), reports a study in North America. However, familiarity with EuroLupus dosing is still low.

Limited health literacy among patients with systemic lupus erythematosus (SLE) contributes to lower knowledge about the disease, a study has shown. The Lupus Knowledge Assessment Test (LKAT) may be improved and used as a screening tool to identify those with knowledge gaps.

Central obesity, as assessed by the waist-to-hip ratio (WHR), is very common in patients with axial spondyloarthritis (axSpA), particularly in women, reveals a recent study. This modifiable comorbidity may result in worse quality of life, worse disease activity, and greater impairment of functional ability.

Short-term tumour necrosis factor (TNF) inhibition with adalimumab falls short of producing improvements in patients with radiographic knee osteoarthritis, according to the proof-of-concept OKINADA trial presented at this year’s European Alliance of Associations for Rheumatology (EULAR) Congress.

The investigational drug ABX464, also known as obefazimod, helps reduce disease activity in patients with rheumatoid arthritis (RA), according to the results of a phase II trial. The 50-mg dose is well tolerated, while the higher dose is associated with mild-to-moderate adverse effects resulting in treatment discontinuation.